In future studies, bile acid administration therapy and the combination of bile acid receptor-specific inhibitors or agonists were used to deeply explore the molecular mechanisms involved in the formation or attenuation of LF caused by the altered bile acids after TACS treatment. The gene discussed is NR1H4; the disease is Lassa fever.